Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Bloomfield

Showing results (461-470 of 583) with videos related to

Pageof 59
Sort By:
Leukemia|September 15, 2016
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)W Blum, B L Sanford, R Klisovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B studyGuido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Leukemia|April 22, 2006
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignanciesM L Slovak, H Gundacker, C D Bloomfield, et al.
Leukemia|March 22, 2017
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemiaA-K Eisfeld, K Mrózek, J Kohlschmidt, et al.
Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.
Leukemia|February 10, 2019
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinicallyKrzysztof Mrózek, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, et al.
Cancer Research|March 15, 1996
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11M A Caligiuri, M P Strout, S A Schichman, et al.
Blood|April 2, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyChristian Langer, Michael D Radmacher, Amy S Ruppert, et al.
Pageof 59

Showing results (461-470 of 583) with videos related to

Sort By:
Pageof 59
Leukemia|September 15, 2016
Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)W Blum, B L Sanford, R Klisovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B studyGuido Marcucci, Krzysztof Mrózek, Amy S Ruppert, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with <i>FLT3</i>-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Blood|August 11, 2011
Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemiaSebastian Schwind, Guido Marcucci, Jessica Kohlschmidt, et al.
Leukemia|April 22, 2006
A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignanciesM L Slovak, H Gundacker, C D Bloomfield, et al.
Leukemia|March 22, 2017
The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemiaA-K Eisfeld, K Mrózek, J Kohlschmidt, et al.
Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.
Leukemia|February 10, 2019
Complex karyotype in de novo acute myeloid leukemia: typical and atypical subtypes differ molecularly and clinicallyKrzysztof Mrózek, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, et al.
Cancer Research|March 15, 1996
Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11M A Caligiuri, M P Strout, S A Schichman, et al.
Blood|April 2, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyChristian Langer, Michael D Radmacher, Amy S Ruppert, et al.
Pageof 59